Apollomics Inc. (APLM) Apollomics, Inc., a biotechnology enterprise established in 2015 and headquartered in Foster City, California, conducts its research and development operations across California, Hangzhou, Shanghai, China, and Australia. The company is dedicated to discovering and advancing innovative oncology treatments to address critical unmet medical requirements. Its therapeutic pipeline features APL-101 (Vebreltinib), a potent and selective c-Met inhibitor being developed for non-small cell lung cancer and other advanced malignancies. Also in development is APL-102, an orally administered, small molecule multiple tyrosine kinase inhibitor intended for liver, breast, and esophageal cancers. Furthermore, APL-122 is an investigational tumor inhibitor candidate focused on treating cancers within the brain. The organization was formerly known as CBT Pharmaceuticals, Inc. before adopting the name Apollomics, Inc. in January 2019.
Sector: Pharmaceutical Preparations
Industry: Biotechnology
Apollomics, Inc. NASDAQ:APLM Healthcare · Biotechnology
CLOSED · Nov 3 $20.92 CLOSED · Nov 3 Prev close $20.84 Close $20.92 VOL 5K $ Vol $102K RVOL 0.33x
Mkt Cap $60.98M
VOL 5K sh
$ Vol $102K
RVOL 0.33×
Press Release
Apollomics Announces $10 Million Private Placement Transaction
Apollomics announced a $10 million private placement consisting of 700,001 Class A ordinary shares, expected to close on or about August 14, 2026.
The transaction includes $8 million in cash proceeds from subscriptions at $15.00 per share and the conversion of a $2 million CEO-held note into equity at a $12.00 per share price.
Insiders including the CEO, CFO, and an affiliate of the COO are participating in the cash portion of the offering.
• 2mo ago AI analysis › Press Release ⚠ 1
Apollomics Regains Full Compliance with Nasdaq Listing Requirements
Apollomics received notification from Nasdaq that it has regained compliance with the Market Value of Listed Securities requirement, closing the matter.
The company had previously failed to maintain the minimum market value of $35 million over 30 consecutive business days but has now met the threshold for the last 10 consecutive business days.
Apollomics is a clinical-stage biopharmaceutical company focused on oncology therapies, with its lead program vebreltinib currently in a Phase 2 multicohort clinical trial.
• 3mo ago AI analysis › Press Release ● Major ⚠ 2
Apollomics Receives Nasdaq Deficiency Notice Regarding Minimum Market Value Requirement and Updates Rights for Vebreltinib (APL-101) in Asia
Apollomics received a notification from Nasdaq that it is not in compliance with the minimum market value of listed securities requirement of $35 million after falling below that threshold for 30 consecutive business days.
The company has 180 calendar days, until December 15, 2026, to regain compliance by maintaining a market value of at least $35 million for ten consecutive business days or face potential delisting.
Separately, the company terminated its collaboration with Launxp International due to a material breach regarding a $3.8 million payment, resulting in Apollomics regaining rights to vebreltinib (APL-101) in Asia.
This reversion consolidates Apollomics' ownership of the asset outside of Mainland China and Macau, providing unencumbered strategic control over clinical development and commercialization in the U.S., Europe, and the Asia-Pacific region.
• 4mo ago AI analysis › Press Release ⚠ 1
Apollomics Reports Full Year 2025 Financial Results and Provides Clinical Updates and Business Progress
Apollomics reported FY2025 revenue of $8.5 million, driven by an upfront payment from partner LaunXP, compared to zero revenue in the prior year.
The company narrowed its net loss to $10.9 million, a significant improvement from the previous year's loss of $53.9 million, following a 64% reduction in operating expenses.
Clinically, the Phase 2 SPARTA study for vebreltinib has enrolled over 280 subjects, with an IND submission for accelerated approval in the U.S. anticipated in the first half of 2027.
Despite the operational turnaround, Apollomics holds only $3.3 million in cash and equivalents as of year-end, raising immediate liquidity concerns given the ongoing burn rate.
• 6mo ago AI analysis › Press Release
Apollomics Inc. Announces $2.0 Million Bridge Financing
globenewswire.com • 7mo ago 
